Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 270M | 224M | 183M | 139M | 117M |
| Gross Profit | 154M | 133M | 113M | 85M | 73M |
| Operating Income | 22M | 18M | 14M | 8M | 12M |
| EBITDA | 50M | 42M | 37M | 25M | 24M |
| Net Income | 15M | 11M | 10M | 6M | 9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$10.45
+0.29% today
1Y Change
+57.85%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viemed Healthcare, Inc. (VMD) is a Healthcare stock with a market cap of $360.00M and listed on NASDAQ. The stock last traded around $10.45 and up 57.9% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +20.5%, EPS growth of +31.0%, a dividend yield of 0.0%. What stands out right now is revenue +20.5%, EPS +31.0%, free cash flow +805.2% with operating margin 8.1% and ROIC 8.8%. Valuation is more restrained than many high-expectation growth names at P/E 24.1 and price/sales 1.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VMD Max Drawdown
-17.06%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$117.1M
-15.7% YoY
FY Net Income
$9.1M
+46.7% YoY
Free Cash Flow
$2.8M
-43.3% YoY
Revenue Growth
+20.5%
EPS Growth
+31.0%
Gross Margin
57.0%
Net Margin
5.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 270M | 224M | 183M | 139M | 117M |
| Gross Profit | 154M | 133M | 113M | 85M | 73M |
| Operating Income | 22M | 18M | 14M | 8M | 12M |
| EBITDA | 50M | 42M | 37M | 25M | 24M |
| Net Income | 15M | 11M | 10M | 6M | 9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 14M | 18M | 13M | 17M | 28M |
| Total Assets | 215M | 177M | 155M | 117M | 118M |
| Total Liabilities | 71M | 44M | 41M | 20M | 23M |
| Shareholder Equity | 142M | 131M | 114M | 97M | 95M |
| Total Debt | 16M | 7M | 10M | 694K | 7M |
| Net Debt | 2M | -11M | -3M | -16M | -22M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22M
-18.9% YoY
Capital Expenditures
20M
+13.8% YoY
Free Cash Flow
3M
-43.3% YoY
Key ratios
Gross Margin
57.0%
Operating Margin
8.1%
Net Margin
5.5%
ROE
10.9%
Debt / Equity
0.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.